Adam Schiffenbauer MD

Adam Schiffenbauer, M.D., is Deputy Head of the Environmental Autoimmunity Group and a clinical investigator in rheumatology, with a special interest in myositis. The mission of the Environmental Autoimmunity Group is to understand the mechanisms for the development of autoimmune diseases so that group members can extend healthy life and reduce the burdens of illness and disability. The group conducts a broad program of clinical, translational, and basic investigations in the area of adult and pediatric autoimmune diseases.

Schiffenbauer leads several research studies and the adult patient enrollment in the group. He serves as principal investigator for several NIEHS protocols, including an investigational drug study evaluating sodium thiosulfate for the treatment of calcinosis, as well as an associate investigator on protocols across several institutes at NIH. Schiffenbauer cares for patients with autoimmune disorders and autoimmune disease mimics, particularly patients with muscle disorders. He also serves as faculty in the NIAMS Rheumatology Fellowship Program and is an attending on the rheumatology consult service. In addition, he serves on several NIH intramural committees, along with serving in leadership roles across national and international consortia that evaluate and conduct a wide range of basic and clinical studies on the idiopathic inflammatory myopathies (IIM).